Literature DB >> 12867628

Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector.

Kate Aspden1, Jo-Ann Passmore1, Friedrich Tiedt1, Anna-Lise Williamson2,1.   

Abstract

Lumpy skin disease virus (LSDV), a capripoxvirus with a host range limited to ruminants, was evaluated as a replication-deficient vaccine vector for use in non-ruminant hosts. By using the rabies virus glycoprotein (RG) as a model antigen, it was demonstrated that recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG in both permissive (ruminant) and non-permissive (non-ruminant) cells. The recombinant LSDV, however, replicated to maturity only in permissive but not in non-permissive cells. Recombinant LSDV-RG was assessed for its ability to generate immunity against RG in non-ruminant hosts (rabbits and mice). Rabbits inoculated with rLSDV-RG produced rabies virus (RV) neutralizing antibodies at levels twofold higher than those reported by the WHO to be protective. BALB/c mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867628     DOI: 10.1099/vir.0.19116-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.

Authors:  Jonathan Cenna; Gene S Tan; Amy B Papaneri; Bernhard Dietzschold; Matthias J Schnell; James P McGettigan
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

2.  Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae).

Authors:  Priscila P Afonso; Patrícia M Silva; Laila C Schnellrath; Desyreé M Jesus; Jianhong Hu; Yajie Yang; Rolf Renne; Marcia Attias; Richard C Condit; Nissin Moussatché; Clarissa R Damaso
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).

Authors:  Yen-Ju Shen; Enid Shephard; Nicola Douglass; Nicolette Johnston; Craig Adams; Carolyn Williamson; Anna-Lise Williamson
Journal:  Virol J       Date:  2011-05-30       Impact factor: 4.099

4.  Engineering of Recombinant Sheep Pox Viruses Expressing Foreign Antigens.

Authors:  Olga Chervyakova; Elmira Tailakova; Nurlan Kozhabergenov; Sandugash Sadikaliyeva; Kulyaisan Sultankulova; Kunsulu Zakarya; Rinat A Maksyutov; Vitaliy Strochkov; Nurlan Sandybayev
Journal:  Microorganisms       Date:  2021-05-07

5.  In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains.

Authors:  Béatrice Pignolet; Jean-Luc Duteyrat; Aude Allemandou; Jacqueline Gelfi; Gilles Foucras; Stéphane Bertagnoli
Journal:  Virol J       Date:  2007-09-27       Impact factor: 4.099

6.  Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model.

Authors:  Kristy Offerman; Armin Deffur; Olivia Carulei; Robert Wilkinson; Nicola Douglass; Anna-Lise Williamson
Journal:  BMC Genomics       Date:  2015-07-08       Impact factor: 3.969

Review 7.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

Review 8.  Immunoprophylaxis against important virus disease of horses, farm animals and birds.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

Review 9.  Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa.

Authors:  Emmanuel Margolin; Wendy A Burgers; Edward D Sturrock; Marc Mendelson; Rosamund Chapman; Nicola Douglass; Anna-Lise Williamson; Edward P Rybicki
Journal:  Nat Rev Microbiol       Date:  2020-09-10       Impact factor: 60.633

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.